MedTrace Logo

Immune Adsorption Role in Treatment of Resistant Lupus

NCT04108611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-10-01

No results posted yet for this study

Summary

Background: lupus is a heterogeneous autoimmune disease with autoantibodies formation. Lupus nephritis carries the worst prognosis. C1q deficiency correlates with activity and renal involvement and may help in its evaluation. Therapies include plasma exchange, immune adsorption and recently under evaluation, hemodiafiltration with on-line endogenous re infusion (HFR), in addition to traditional immunosuppressive therapies. Aim: is to evaluate the role of HFR in improving signs and symptoms of SLE activity and laboratory parameters not responding to traditional immune suppressive therapy

Conditions

  • Systemic Lupus

Interventions

PROCEDURE

hemodiafiltration with endogenous re infusion (HFR)

hemodiafiltration with endogenous re infusion (HFR) for cases 2

Sponsors & Collaborators

  • Dr. Mohamed Ahmed El ghiriani

    lead OTHER

Principal Investigators

  • Naga S Salah, Professor · University of Alexandria

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-05-01
Completion
2019-09-25

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04108611 on ClinicalTrials.gov